AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
Short Wave
Introduction
A new drug for alseimer's disease is being marketed under the brand name adhelm. The food and drug administration approve this drug in june, but sales figures show that it's reaching very few patients. Why are so few people taking this drug? What end? A lot of things, but the short answer is that aduhelm has a major image problem.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode